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Abstract 
Background:  To evaluate safety and efficacy of ipilimumab combined with standard first-line 
chemotherapy for patients with extensive stage SCLC.  
Methods: Chemotherapy-naïve extensive stage SCLC patients were treated with carboplatin and 
etoposide up to six cycles. Ipilimumab 10 mg/kg was given on day 1 of cycles 3-6 and every 12 
weeks. Response was assessed by RECIST v1.0 and immune related response criteria (irRC). The 
primary endpoint was 1-year progression-free survival (PFS) according to RECIST. Secondary 
endpoints included PFS by irRC (irPFS) and overall survival (OS). Autoantibody serum levels were 
evaluated and correlated with clinical outcomes. 
Results: 42 patients were enrolled between September 2011-April 2014, 39 evaluable for safety and 
38 for efficacy.   6/38 patients (15.8% [95% CI: 7.4%-30.4%]) were alive and progression-free at 1-
year by RECIST. Median PFS was 6.9 months (95%CI: 5.5-7.9).  Median irPFS was 7.3 months (95% 
CI: 5.5-8.8). Median OS was 17.0 months (95% CI: 7.9-24.3). In patients evaluable for response, 
21/29 patients (72.4%) achieved an objective response by RECIST and 28/33 (84.8%) by irRC. All 
patients experienced at least one adverse event; 35/39 (89.7%) patients developed at least one toxicity 
≥ Grade 3; in 27 (69.2%) this was related to ipilimumab. Five deaths were reported to be related to 
ipilimumab. The positivity of an autoimmune profile at baseline was associated with improved 
outcomes and severe neurological toxicity. 
Conclusion: Ipilimumab in combination with carboplatin and etoposide might benefit a subgroup of 
patients with advanced S LC. Autoantibody analysis correlates with treatment benefit and toxicity 
and warrants further investigation.  
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Introduction 
Small Cell Lung Cancer (SCLC) accounts for around 15-20% of all lung cancers. Despite the high 
percentage of initial responses to chemotherapy, overall prognosis remains dismal, with median 
survival times of 9.5 months for extensive stage disease 1. No therapeutic strategy except for the 
addition of radiotherapy to chemotherapy has produced improvements in survival 2-7. 
Harnessing the immune response to attack tumor cells with antibodies directed against checkpoint 
molecules has had dramatic impact in the treatment of melanoma 8, 9 and other solid tumors 10, 11.  
Clinical evidence supports immune recognition of SCLC, in the form of paraneoplastic immune 
mediated syndromes (PNS). PNS are associated with the cross reactivity of immune responses with 
self-antigens, frequently neuronal antigens, physiologically expressed by the normal nervous system 
and ectopically by cancer cells 12 but the T-cell based mechanisms for PN events remains poorly 
understood 13. The presence of autoimmune disease seems to be associated with better outcomes 14, 15. 
These findings suggest that the effective antitumor immune responses are linked to autoimmune 
manifestations16. 
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is expressed by lymphocytes early in the adaptive 
immune response, and binds to B7 expressed in antigen presenting cells to downregulate T-cell 
responses 17. Additionally, CTLA-4 is highly expressed on regulatory T-cells and antibody binding to 
CTLA-4 leads to their removal by antibody dependent cytotoxicity 18. Release of these “brakes” with 
anti-CTLA-4 antibodies has been successfully tested in several tumors. 
Ipilimumab is an anti-CTLA-4 antibody approved for the treatment of metastatic melanoma 8, 19, 20. It 
is however unclear, how effective ipilimumab is in rapidly progressing tumors, such as SCLC. 
However, chemotherapy for SCLC is effective in killing tumor cells and cell death will release tumor 
antigen 21. It is therefore possible that in the context of immune modulation with ipilimumab, 
recognition of these antigens might induce clinically useful anti-tumor immunity. 
In 2013, a study was published assessing ipilimumab added to carboplatin and paclitaxel randomizing 
patients with extensive stage SCLC to only chemotherapy, or chemotherapy with concurrent or 
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phased ipilimumab 22. This study suggested that phased ipilimumab after two cycles of chemotherapy 
was a promising strategy.  
The current study enrolled patients with extensive stage SCLC treated with standard carboplatin and 
etoposide in the first line setting and aimed to evaluate the safety and efficacy of ipilimumab added to 
this combination and explore predictive biomarkers (ClinicalTrials.gov Identifier:NCT01331525).  
 
Patients and methods 
Patient population 
Eligible patients were men and women aged ≥18 who had a histological or cytological diagnosis of 
SCLC, no previous systemic therapy for SCLC, an Eastern Cooperative Oncology Group performance 
status of  0 or 1, adequate baseline laboratory tests and no active or chronic infection with HIV, 
Hepatitis B, or Hepatitis C. Exclusion criteria included: limited stage SCLC appropriate for radical 
treatment with chemoirradiation, symptomatic CNS metastases, autoimmune disease, live vaccines 
(for up to 1 month before or after any dose of ipilimumab), a history of prior treatment with a CD137 
agonist or CTLA-4 inhibitor or agonist and concomitant therapy with any of the following: 
Interleukin-2, interferon, or other immunotherapy regimens; immunosuppressive agents; other 
investigational therapies; or chronic use of systemic corticosteroids. 
 
Study design and treatment plan 
This single stage non-randomized phase II study examined the efficacy and toxicity of ipilimumab (10 
mg/kg) together with carboplatin AUC=6, IV on day 1 and etoposide 120 mg/m2 IV Day1, 100mg 
BD PO days 2 and 3, every 21 days (ICE). Patients could enroll the trial at any point up until cycle 3. 
Patients received carboplatin and etoposide up to 6 cycles. Chemotherapy was discontinued in the 
event of progressive disease (RECIST v1.0) or excessive toxicity. Ipilimumab 10 mg/kg was given IV 
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on day 1 of chemotherapy cycles 3-6 and then once every 12-weeks from week 30 until immune 
related disease progression or excessive toxicity.   
Patients could be offered prophylactic cranial irradiation (PCI) after completion of induction 
chemoimmunotherapy.  
The trial was conducted in accordance with good clinical practice and ethical approval was obtained 
(MREC 10/H0502/95; ISRCTN: 14095893); written informed consent was provided by all patients 
before enrolment. 
Study assessments 
Tumor assessments were conducted by computerized tomography (CT) 6-weekly for the first year 
(until week 54), then 12-weekly until disease progression by both RECIST v1.0 and immune response 
criteria (irRC)23. A baseline brain CT scan (not MRI) was performed for CNS disease evaluation if 
clinically indicated. 
Patients who received at least one dose of ipilimumab were considered evaluable for safety, assessed 
using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE), Version 4.0 (http://ctep.cancer.gov). As no safety data was available for the combination, a 
planned interim safety monitoring assessment was performed. Once, 9 patients had been treated with 
the combination for at least 6 weeks a first clinical safety assessment was performed to identify any 
early safety signals from ipilimumab given in combination with Carboplatin and Etoposide. In 
addition, a review of safety was triggered throughout the trial: if Ӌ 40% of patients treated develop a Ӌ 
Grade 3 toxicity thought to be related to the study drugs; or if Ӌ 10% of patients experience an 
unexpected Ipilimumab -related Ӌ Grade 3 toxicity that could not be alleviated or controlled by 
appropriate care and/or steroid and/or infliximab therapy within 14 days of the initiation of such 
therapy; or in response to any Ipilimumab-related deaths unless attributed to disease progression. 
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 Data on adverse events (AEs) and immune related AEs (irAEs) were collected at each study visit and 
until 90 days after the last ipilimumab dose. irAE was defined as an AE that was treatment related and 
considered to be immune mediated.  
irAEs were managed according to international guidelines and package inserts/product label. No dose 
reductions were allowed for ipilimumab. Dose modifications for carboplatin and etoposide were 
according to local practice.  
Biomarker assessment  
Detection of autoantibodies was performed at baseline and during follow up in cases where clinically 
indicated. Anti-VGCC and VGKC antibodies were determined with radio-immunoprecipitation 
assays24, 25. Antibodies against intracellular neuronal antigens were detected using indirect 
immunohistochemistry on primate cerebellum (NOVA Lite, Inova, Werfen, Warrginton, UK), 
immunoblotting (Ravo PNS Blot, ravo Diagnostika, Freiberg, Germany) and a semi-automated 
ELISA26. Interpretation was done according to protocol instructions.  
 
Statistical analysis 
The sample size was based on A’Hern’s single stage phase II design, with two-sided significance 
level of 0.05, 80% power, p0 (clinically uninteresting true PFS according to RECIST v1.0)=10%; and 
p1 (sufficiently promising true PFS according to RECIST v1.0)=25%. The design required recruiting 
40 evaluable patients, and the efficacy of the treatment was considered to be worth developing further 
if eight or more patients were alive and progression-free at 1-year.  
The intention-to-treat (ITT) population consisted of all registered patients. Toxicity was assessed 
using the safety population which excluded patients who did not receive any ipilimumab. Baseline, 
treatment and efficacy information was performed on the efficacy analysis population that consisted 
of all eligible patients included in the safety population.  
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Outcome analysis 
The primary endpoint was 1-year progression-free survival (PFS) according to RECIST v1.0. PFS 
was defined as the time from day 1 of the 1st cycle of chemotherapy to the date of progression or death 
from any cause.  
Secondary endpoints included PFS; PFS by irRC (irPFS); overall survival (OS), defined as the time 
from the date of day 1, cycle 1 of chemotherapy to the date of death from any cause; best overall 
response, defined as the maximum response by RECIST v1.0 compared to the baseline scan at study 
entry; duration of response, defined as the time from first response by RECIST v1.0 to disease 
progression or death from any cause; duration of response by irRC; and toxicity assessment according 
to NCI CTCAE v4.0. 
Patients who had not died or progressed were censored for survival endpoints at the last documented 
clinical review. Survival analyses were performed using Kaplan-Meier estimates, and 95% confidence 
intervals (CIs) for proportions were calculated using the Wilson Interval as recommended for small n 
by Brown et al.27 Summary statistics and plots were used to examine other secondary endpoints and to 
characterize response rates.  
Immunological data was recorded for each patient. Ad-hoc exploratory analysis was carried out to 
assess associations between antibody positivity and clinical outcomes (irRC, irPFS, OS and toxicity 
occurrence). 
Results 
Patients and treatment 
Forty-two patients with no previous systemic therapy for SCLC were registered into this study 
between September 2011 and April 2014 at six sites in the UK (Figure 1 CONSORT diagram). Three 
patients withdrew from the trial prior to receiving ipilimumab and one patient was retrospectively 
diagnosed with atypical carcinoid. Baseline demographics and disease characteristics are shown in 
Table 1 for the evaluable population (n=38). The majority of patients were male (66%), with a 
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performance status (PS) of 1 (66%) and involvement of the lung, lymph nodes and liver. The presence 
of autoantibodies was investigated at baseline in 38 patients (Table 2). Seventeen (45%) patients had 
at least one confirmed positive autoimmune antibody at baseline. 
At the final database lock (03 November 2015) after a minimum follow up of 6.8 months (median 8.5 
months) no patients were still receiving treatment.  
The main reason for treatment discontinuation was toxicity (10/39, 26%). 
Thirty-seven out of 38 patients started ipilimumab treatment on the third cycle of chemotherapy. The 
median number of cycles of the combination treatment for the efficacy analysis population (n=38) 
was six (range 3-6). Twenty-four patients (63%) completed the chemoimmunotherapy phase.  
Twenty-three patients (61%) had at least one chemotherapy dose delayed and 15 (40%) had dose 
modifications. Fifteen patients (40%) had at least one dose of ipilimumab delayed and 13 (34%) 
missed at least one dose during the combination phase. The number of patients who received at least 
one maintenance dose of ipilimumab was nine (24%) and one patient received treatment for 78 weeks.  
Nine patients (24%) received PCI and eight (21%) radiotherapy to the chest. 
 
Efficacy 
Six out of 38 patients (efficacy analysis population) (15.8% [95% CI: 7.4%-30.4%]) were 
progression-free at 1-year by RECIST. Median PFS was 6.9 months (95%CI: 5.5-7.9) (Figure 2).  
Median irPFS was 7.3 months (95% CI: 5.5-8.8) with an irPFS at 1-year of 12.6% (95% CI: 4.0%-
26.3%). Median OS was 17.0 months (95% CI: 7.9-24.3) (Figure 3). Response information by 
RECIST and irRC was available on 29 and 33 patients, respectively, of whom 21 (72.4%) achieved an 
objective response according to RECIST criteria and 28 (84.8%) according to irRC (Table 3). 
Supplementary Table 1 compares both patterns of response. 
Patients receiving PCI had a numerically superior OS (median 18.5 vs 12.3 months respectively) but 
this difference did not reach statistical significance (p=0.447). 
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Safety  
All toxicities are listed in Supplementary Table 2. Table 4 summarizes the incidence of treatment 
related grade 3 or higher AEs for the safety analysis population (n=39). All patients experienced at 
least one AE. Thirty-five (90%) patients developed at least one > grade 3 toxicity; in 27 (69%) this 
toxicity was thought to be related to ipilimumab. Neurological AEs were reported for 19 patients 
(49%), although only four patients (10%) experienced 5 high grade AEs and three (8%) among these 
were related to ipilimumab. Two patients developed central neuropathies (described as mild 
encephalopathy and cerebellar syndromes, mimicking PNS) and one had severe headaches with 
deterioration of performance status. No association was observed between the occurrence of 
neurological toxicity and PCI treatment.  
Other frequent AEs, probably irAEs were diarrhea in 28 patients (72%) and skin rash in 20 patients 
(51%), respectively. For 18 patients (46%) treatment delays were associated with ipilimumab related 
toxicity. Five deaths (13%) were reported to be related to ipilimumab. Two of the deaths happened 
while the patients where on treatment or shortly after (cardiac arrest, neutropenic sepsis) but the 3 
remaining happened 4-5 months after the last treatment (pneumonia, autoimmune encephalitis and 
sepsis). 
In an unplanned analysis, we evaluated if severity of irAEs was associated with outcome. Patients 
who had more severe (G3 or above) irAEs had numerically worse OS (Supplementary Figure 1), but 
this was not statistically significant. Moreover, 73% of patients with G1/2 irAEs were alive at 1-year 
when compared to 47% of patients with severe (G3 or above) irAEs. 
Autoantibodies as predictive biomarkers 
In an ad-hoc analysis, we explored the association between positivity of autoantibodies at baseline 
and clinical outcomes. 
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The most frequently detected antibodies were ANA in 10 patients and anti-SOX2 in 9 patients (Table 
2). Twenty-three patients (60.5%) had at least one positive autoantibody detection. Antineuronal 
antibodies were more frequently positive (44.7%) than the rest of the autoantibodies (31.6%). We 
assessed the association between autoantibodies and response (irRC). We found that 0/14 patients 
with positive antineuronal antibodies vs 5/19 patients with no positivity showed irSD/irPD (p=0.049). 
Any autoantibody positivity showed a trend to association with response (p=0.066).We then evaluated 
the association between autoantibody positivity and irPFS. We observed that patients with any 
positive autoantibody detected at baseline experienced a significantly longer median irPFS (8.8 m 
(95%CI 5.1-10.7) vs 7.3 m (95%CI: 2.9-7.9; p=0.036) (Figure 2C). ANA positivity predicted for a 
significantly prolonged irPFS (10.2 m vs 6.9 m; p=0.032). Patients with any positive autoimmune 
antibody showed a trend to prolonged survival (18.5 m vs 17 m); p=0.144) (Figure 3B).  
We assessed the correlation between autoantibodies and toxicity.  We found that 3/15 patients with 
positivity for SOX2 and/or anti-Hu antibodies presented ipilimumab related G3 or above neurological 
toxicity, compared to 0/23 patients with negativity for these antibodies (p=0.054).  One of these 
patients had more than one positive antineuronal autoantibody (anti-SOX2 and anti-Yo).  
Discussion 
In our trial, we observed substantial excess toxicity from the ICE combination, which made the 
delivery of the chemoimmunotherapy and the maintenance ipilimumab challenging. Delays were 
frequent as were interruptions of treatment due to toxicity.  
Ipilimumab has a well-defined toxicity profile, and combination treatments have shown increased 
toxicity when compared to monotherapy. In the current study, the grade 3 or above toxicity rate is 
considerably higher (69%) (including five treatment related deaths). These figures are significantly 
higher than the toxicity reported in the randomised trial by Reck et al. 22, ranging from 43-50% (1 
toxic death in the concurrent arm). This increased toxicity might be explained by the better tolerance 
of the chemotherapy regime used in that study and might also reflect excess toxicity from combining 
ipilimumab and etoposide. Combining a third drug (i.e. sunitinib, thalidomide) with the platinum and 
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etoposide doublet in advanced SCLC has been challenging due to increased toxic death rates6, 7 and 
protocols have been amended to pursue a maintenance strategy6. Moreover, the dose used in this study 
(10mg/kg) was higher than the dose currently approved for melanoma (3mg/kg) and data suggests 
increased toxicity with higher doses 28. Therefore, using ipilimumab at 3mg/kg might be more 
appropriate in combination as well as a sequential approach of immunotherapy after chemotherapy. 
Newer agents, such as anti-PD-1/PD-L1 drugs, with a more favorable toxicity profile might be easier 
to combine with chemotherapy. Moreover, ipilimumab in combination with the anti-PD-1 nivolumab 
seems to have an acceptable toxicity profile and adds clinical benefit in early phase testing in patients 
with SCLC 29.  
In our study, G3 or above ipilimumab related neurological toxicity rate was 7.6%. A comprehensive 
study of the prevalence of neurological PNS in a similar population of SCLC observed that 9.1% of 
patients had a PNS by clinical evaluation 30, the majority (83%) having symptoms preceding the 
diagnosis of SCLC. Patients with clinical evidence of autoimmunity were however excluded in our 
study. As neurological toxicities developed after treatment initiation, they are most likely treatment-
related.  Autoimmunity to the intracellular antigens SOX2 and Hu has been associated with PNS in 
several publications 30-33. Our exploratory analysis revealed an association between anti-SOX2 and Hu 
autoantibodies and severe neurological toxicities. Among patients with anti-SOX2 or anti-Hu 
antibodies at baseline we could not find differences (in antibody titers or subsequent antibody levels 
(Suppl Fig 2)) between those who developed neurological syndromes or not. The absence of anti-
neuronal autoantibodies at diagnosis might therefore reflect a decreased likelihood of developing 
severe neurological toxicities triggered by ipilimumab. This suggests that careful monitoring of 
neurological symptoms in patients with anti-neuronal autoantibodies at baseline is important if 
immunotherapy is chosen as a strategy. We recognize that these findings need further validation and 
may additionally reflect the particular method of action of ipilimumab. 
Our study is not randomized and therefore we cannot rule out that the neurological syndromes we 
clinically attributed to ipilimumab might have happened regardless of treatment with this drug. Of the 
3 patients with severe neurological toxicity mimicking PNS, in 2 of the cases the onset of the 
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neurological syndrome preceded and perhaps therefore heralded disease progression. In the remaining 
case the progression was observed before the PNS. Thus, it remains possible that in spite of absence 
of PNS at primary diagnosis, the neurological syndrome post-treatment was caused by progression-
related cross-reactive immune responses. 
Markers of Treg function are lower in patients with autoantibodies and concomitant PNS as compared 
with those with no neurological syndromes 34. Tregs express high levels of CTLA-4 and are 
downregulated or removed by ipilimumab, and this is a desirable effect to enhance immune response 
against the tumor 35, 36. Our data are consistent with the hypothesis that downregulation of Tregs in 
patients with anti-neuronal autoantibodies by ipilimumab could promote development of autoimmune 
PNS.   
The primary endpoint of the study was not met. Median PFS was 6.9 months. Interestingly, although 
irPFS seems to better reflect the efficacy of immunotherapeutic agents, in our study both parameters 
gave similar results (median irPFS of 7.3 months). These results are consistent with the 6.4 months 
median irPFS observed in the phased-ipilimumab arm in Reck et al. study 22.  Four patients with PD 
according to RECIST criteria were classified as responders or SD according to irRC. In other tumor 
types, patients with RECIST-defined PD but irRC-defined response or SD seem to have better 
outcome than those with progressive disease according to both parameters 37. There is no previous 
assessment of this question in SCLC. Due to the low numbers, we were not able to compare survival 
of these patients to the RECIST responders. 
A key secondary endpoint was OS. Although this is a relatively small cohort and cannot be directly 
compared with other studies, the median OS of 17 months exceeds the OS reported in other recent 
trials in this setting 6, 22 which is around 14 months. Interestingly, this happened despite the low rate 
(24%) of patients receiving PCI or thoracic radiotherapy. Fifty-six percent of the patients were alive at 
1-year, 29% at 2-years and almost 10% at 3 years. This is consistent with findings in other studies 
where improved OS is the key benefit from ipilimumab 19. More definitive data about the potential 
benefit of this combination will be available from the completed randomized trial (NCT 01450761). 
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To investigate potential biomarkers of benefit, we evaluated the association between autoimmunity 
and outcomes. We observed that a positive autoimmune profile at baseline predicted better response, 
irPFS with a trend to increased survival. The presence of autoantibodies at baseline has been linked to 
prognosis in this disease with conflicting results 31, 33, 38-40. Overall, there is evidence of patients 
benefiting from naturally occurring tumor immunity with improved responses to tumor treatment or, 
in rare cases, complete eradication of tumor without tumor treatment 41-43. 
This would be consistent with our results suggesting that a pre-existing immune response enhanced by 
ipilimumab could result in beneficial effect from this drug. Although interesting, these results are 
hypothesis generating and need further validation. Moreover, the lack of a control only-chemotherapy 
arm precludes us from demonstrating the predictive vs a merely prognostic role. 
In conclusion, ipilimumab in combination with carboplatin and etoposide as first-line treatment for 
SCLC shows beneficial effects, particularly in patients with pre-existing autoimmunity. However, 
toxicity was significant, suggesting that sequential immunotherapy after chemotherapy might be a 
more feasible approach, maybe in combination with other immune modulators such as PD-1 or PD-L1 
inhibitors. More work in needed to demonstrate if autoantibodies can serve as biomarkers for toxicity. 
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Figure legends 
Figure 1. CONSORT diagram showing the disposition of patients in the ICE study  
Figure 2. Kaplan-Meier plots for progression free survival according to RECIST v1.0 criteria (A) and 
immune related response criteria (B) and according to autoantibody status at baseline (C) 
Figure 3. Kaplan-Meier plots for overall survival (A) and according to autoantibody status at baseline 
(B) 
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Table 1. Baseline patient demographics and disease characteristics (efficacy population n=38) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IgG=Immunoglobulin G. IgA=Immunoglobulin A. IgM=Immunoglobulin M. LDH=Lactate 
Dehydrogenase. CNS=Central Nervous System.  
Denominator is non-missing data for the analysis population for each test performed 
 
 
  
Demographic or disease 
characteristics 
n (%) 
Age, years  
Median 63 
Range 44-84 
Sex  
Female 13 (34.2) 
Male 25 (65.8) 
ECOG PS  
0 11 (34.4) 
1 21 (65.6) 
Missing 6 
Index and non-index lesions  
Lung 27 (71.1) 
Lymph node 27 (71.1) 
Liver 15 (39.5) 
Bone 3 (7.9) 
CNS 1 (2.6) 
Effusion 2 (5.3) 
Soft tissue 7 (18.4) 
Other 13 (34.2) 
LDH (IU/L)  
Median 398 
Range 186-1252 
Missing 4 
IgG (g/L)                   
Median 8.10 
Range 0-18.00 
Not performed/missing 3 
IgA(g/L)                     
Median 2.20 
Range 0.70-4.20 
Not performed/missing 4 
IgM(g/L)  
Median 0.75 
Range 0.20-2.60 
Not performed/missing 4 
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Table 2. Autoantibody analysis at baseline (efficacy population n=38) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VGCCA=Voltage-Gated Calcium Channel Antibody. VGPCA=Anti-Voltage Gated Potassium 
Channel Antibodies. ANA= anti-nuclear antibodies. ANCA= anti-neutrophil cytoplasmic antibodies 
Denominator is non-missing data for the analysis population for each test performed 
Autoantibody assays N (%) 
Anti-SOX2  
Positive 9 (23.7%) 
Negative 29 (76.3%) 
Not performed/missing 0 
Anti-Hu  
Positive 6 (15.8%) 
Negative 32 (84.2%) 
Not performed/missing 0 
Anti-Yo  
Positive 2 (6.5) 
Negative 29 (93.5) 
Not performed/missing 7 
Anti VGCCA  
Positive 0 
Negative 24 (100) 
Not performed/missing 14 
Anti VGPCA  
Positive 2 (8.3) 
Negative 22 (91.7) 
Not performed/missing 14 
Thyroid peroxidase  
Positive 4 (16.0) 
Negative 21 (84.0) 
Not performed/missing 13 
Rheumatoid factors   
Positive 3 (12.5) 
Negative 21 (87.5) 
Not performed/missing 14 
Anti-muscle antibodies  
Positive 0 
Negative 33 (100) 
Not performed/missing 5 
ANA  
Positive 10 (28.6) 
Negative 25 (71.4) 
Not performed/missing 3 
ANCA  
Positive 2 (8.3) 
Negative 22 (91.7) 
Not performed/missing 14 
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Table 3. Best overall tumour response (efficacy population n=38) 
 
Tumour response  
RECIST v1.0  n (%) 
Complete response 1 (3.4%)  
 
Partial response 20 (69.0%) 
Stable disease 3 (10.3%) 
Progressive disease 5 (17.2%) 
Not assessed/missing 9 
Immune-related response 
criteria (irRC) 
 
Complete response 2 (6.1%) 
Partial response 26 (78.8%) 
Stable disease 5 (15.2%) 
Progressive disease 0 
Not assessed/missing 5 
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Table 4. Summary of grade 3 or above toxicities (patients receiving at least 1 cycle of 
ipilimumab, n=39) 
Toxicity Total Ipilimumab1 Carboplatin1 Etoposide1 
Patients with at least one 
Grade 3 or above AE 
35 (89.7%) 27 (69.2%) 25 (64.1%) 25(64.1%) 
Neurological     
Generalised muscle 
weakness 
1 (2.6%) 1 (2.6%) 0 0 
Headache 1 (2.6%) 1 (2.6%) 0 0 
Agitation 1 (2.6%) 1 (2.6%) 0 0 
Nervous system disorder 1 (2.6%) 1 (2.6%) 0 0 
Central neuropathy 1 (2.6%) 1 (2.6%) 0 0 
Other immune related     
ALT 
increase/transaminitis 
3 (7.7%) 3 (7.7%) 0 0 
Alkalyne phosphatase 
increase 
3 (7.7%) 3 (7.7%) 0 0 
Autoimmune disorder 2  (5.1%) 2  (5.1%) 0 0 
Colitis*/diarrhoea 19 (48.7%) 19 (48.7%) 6 (15.4%) 7 (18%) 
Hyperglycemia 2  (5.1%) 1 (2.6%) 1 (2.6%) 1 (2.6%) 
Lymphocyte count 
decrease 
2  (5.1%) 0 1 (2.6%) 1 (2.6%) 
Neutrophil count decrease 9 (23.1%) 2  (5.1%) 8 (20.5%) 8 (20.5%) 
Rash 1 (2.6%) 1 (2.6%) 0 0 
Thrombocytopenia 2  (5.1%) 1 (2.6%) 2  (5.1%) 2  (5.1%) 
Other     
Anaemia 6 (15.4%) 0 6 (15.4%) 6 (15.4%) 
Dyspnoea 3 (7.7%) 1 (2.6%) 1 (2.6%) 1 (2.6%) 
Fatigue 3 (7.7%) 1 (2.6%) 2  (5.1%) 2  (5.1%) 
Febrile neutropenia 3 (7.7%) 0 2  (5.1%) 2  (5.1%) 
Hyponatraemia 3 (7.7%) 0 1 (2.6%) 0 
Infection 11 (28.2%) 3 (7.7%) 7 (18%) 7 (18%) 
Sepsis 4 (10.3%) 2  (5.1%) 2  (5.1%) 2  (5.1%) 
Thromboembolic event 2  (5.1%) 2  (5.1%) 2  (5.1%) 2  (5.1%) 
     
* One case of ileitis is included 
1
 Toxicities assessed by site principal investigator to be definitely, probably or possibly related to 
study drug 
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